September 8, 2011 — Naviscan announced it obtained CE Mark approval for its high-resolution positron emission tomography (PET) scanner and PET-guided biopsy accessory. The breast application of the scanner is positron emission mammography (PEM). Naviscan has expanded its distribution into 13 European countries and has already received its first two orders in Germany and Switzerland.

The company manufactures the only commercially available, high-resolution PET scanner with PET-guided biopsy system. The scanner uses PET technology to produce tomographic images allowing physicians to visualize breast tumors with an unprecedented resolution of 1.6 mm, about the width of a grain of rice.

In recently published data, PEM has been found to be significantly more precise than existing technologies at identifying benign and cancerous lesions, in what scientists call "specificity." This reduces the number of unnecessary biopsies. It is a welcomed outcome for women and physicians looking to reduce patient trauma and cost associated with unnecessary procedures.

The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the United States and other parts of the world.

For more information: www.naviscan.com


Related Content

News | Breast Imaging

Feb. 16, 2026 — Rising demand for breast cancer screening and diagnostics is outpacing the supply of available breast ...

Time February 17, 2026
arrow
News | Radiology Imaging

Feb. 12, 2026 — Siemens Healthineers and Mayo Clinic are expanding their strategic collaboration to enhance patient care ...

Time February 13, 2026
arrow
News | FDA

Jan. 29, 2026 — GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MIM ...

Time February 03, 2026
arrow
News | PET Imaging

Jan. 26, 2026 — Nuclidium, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...

Time January 27, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — VizMark has received U.S. Food and Drug Administration FDA 510k clearance for VM1, a non-metal visual ...

Time January 19, 2026
arrow
News | Radiation Oncology

Jan. 8, 2026 — RefleXion Medical, an external-beam theranostic oncology company, has announced the U.S. Food and Drug ...

Time January 13, 2026
arrow
News | Women's Health

Dec. 12. 2025 — A new study has found that an individualized approach to breast cancer screening that assesses patients’ ...

Time December 17, 2025
arrow
News | Breast Imaging

Dec. 16, 2025 — Hologic, Inc, a medical technology company dedicated to improving women’s health, recently announced new ...

Time December 16, 2025
arrow
News | FDA

Dec. 8, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, has submitted a 510(k) premarket ...

Time December 08, 2025
arrow
News | Breast Imaging

Dec. 01, 2025 — DeepHealth, a wholly owned subsidiary of RadNet, Inc., has launched the DeepHealth Breast Suite,2 an end ...

Time December 04, 2025
arrow
Subscribe Now